2025 International Congress » Parkinson’s Disease: Clinical Trials

A Comparison of Coordinated Reset and Low-Frequency Vibrotactile Stimulation for the Treatment of Parkinson’s Symptoms

E. Kabasenche, M. Gutierrez, M. Fisher, C. Hauptmann, P. Luu, D. Tucker (Eugene, USA)

A Double-Blind, Cross-Over Pilot Study Comparing Adaptive Deep Brain Stimulation (aDBS) to Conventional DBS in Parkinson’s Disease

T. Hashimoto, J. Tanimura, T. Yako (Matsumoto, Japan)

A Phase 1b Study to Investigate Safety and Tolerability of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson’s Disease

K. Holmström, K. Jääskeläinen, N. Kulesskaya, J. Koskinen, R. Holmnäs, A. Vuolanto, A. Domanska, M. Engström, P. Vainio, M. Scheinin, C. Videbaek, A. Tornio, Z. Lovro, F. Scheperjans, J. Rinne, H. Huttunen (Espoo, Finland)

A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease

M. Werner, C. Meyer, E. Mancino, C. Klint, J. Pellecchia, A. Mcgarry, K. Kieburtz, C. Olanow (Atlanta, USA)

A Phase I Study of TR-012001, a Nasal Levodopa, in Healthy Adult Japanese Male Subjects

R. Ise, M. Kaneko, S. Haruta, Y. Sonoda, Y. Akiyoshi, C. Date, S. Nakano, T. Akagi, Y. Sumiyoshi, S. Kanazashi, I. Nagata, H. Fukase (Tokyo, Japan)

A Phase II Randomized, Parallel, Double-blind, Placebo-controlled Study of the Efficacy and Safety of WD-1603 in Subjects with Parkinson’s Disease

X. Wei, L. Chen, X. Hu, J. Guo, C. Liu, J. Wang (Shanghai, China)

A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients With Parkinson’s Disease With OFF Episodes, Without Dopa Decarboxylase Inhibitor

M. Nomoto, H. Yabe, R. Ando, Y. Sumiyoshi, T. Akagi, R. Ise, Y. Akiyoshi, C. Date, S. Nakano, R. Suzuki, Y. Sonoda, S. Haruta, S. Kanazashi, A. Mori, I. Nagata (Tokyo, Japan)

A randomised controlled feasibility study of a technology-assisted home-based aerobic exercise program for individuals with Parkinson’s disease

S. Neo, Z. Yee, W. Li, HL. Ng, R. Hoe, C. Chung (Singapore, Singapore)

A Randomized Clinical Trial of Immersive Virtual Reality and Cognitive Rehabilitation for Mild Cognitive Impairment in Parkinson’s Disease

A. Puig-Davi, A. Moreu-Valls, S. Martinez-Horta, G. Kulisevsky, J. Rodriguez-Antiguedad, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the NLRP3 Inhibitor Vent-02 in Patients with Mild to Moderate Parkinson’s Disease

A. Matta, X. Valencia, K. Pike, L. Warner, O. Spiegelstein, M. Bigal (Waltham, USA)

A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s

G. Mills, M-L. Zeissler, O. Bandmann, R. Barker, J. Carpenter, S. Collins, J. Duffen, S. Gandhi, L. Houlden, C. Gonzalez-Robles, C. Mcalpine, K. Mcfarthing, C. Pugh, A. Schapira, A. Schrag, C. Shakeshaft, T. Foltynie, C. Carroll (London, United Kingdom)

Adaptive Deep Brain Stimulation for Parkinson’s Disease in Routine Clinical Care: First Experiences

B. Keulen, M. de Neeling, M. Stam, D. Hubers, L. Boon, R. de Bie, B. van Wijk, P. Schuurman, M. Bot, M. Beudel (Amsterdam, Netherlands)

Adaptive deep brain stimulation for tremor control in Parkinson’s disease

A. Ramirez-Zamora, T. Herrington, M. Beudel, J. Ostrem, S. Little, L. Almeida, A. Fasano, T. Hassell, K. Mitchell, E. Moro, M. Gostkowski, N. Sarangmat, L. Tonder, Y. Tan, R. Summers, N. Morelli, H. Bronte-Stewart (Gainesville, USA)

An Exercise Prescription to Slow the Progression of Parkinson’s Disease

J. Alberts, A. Rosenfeldt, C. Lopez-Lennon, E. Jansen, C. Felix, E. Zimmerman, P. Imrey, H. Fernandez, K. Mckee, L. Dibble (Cleveland, USA)

Anti-Diabetic Medications to Fight Parkinson’s Disease and Lewy Body Dementia

T. Chmiela, J. Dulski, Z. Parrales, Z. Wszolek, J. Wilson (Jacksonville, USA)

Barriers and Facilitators of Adherence to Mediterranean-Ketogenic and MCT-Supplemented Mediterranean Diets in Parkinson’s Disease: A Qualitative Secondary Analysis from a Random-Order Crossover Trial

K. Tosefsky, Y. Wang, J. Lam, A. Kuan, S. Appel-Cresswell (Vancouver, Canada)

Changes in Motor States Throughout the Waking Day With Tavapadon in People With Parkinson’s Disease

R. Hauser, R. Pahwa, L. Harmer, A. Lind (Tampa, USA)

Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson’s disease

S. Isaacson, F. Amjad, S. Thakkar, D. Martins, H. Brigas, G. Banisadr, S. Fisher (Boca Raton, USA)

Comparative Study of limits of stability Improvements in Young-Onset vs. Late-Onset Parkinson’s Disease Following One-Year Biofeedback Balance Training

MYA. Amine, YM. Mahmoud, FAR. Mehana, MAY. Hosny (Cairo, Egypt)

Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years

H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Floro, N. Abid, V. Tabar (New York, USA)

Continuous Subcutaneous Apomorphine Infusion (CSAI) Reduces OFF Periods and Extends Periods of GOOD ON Time: Heatmap Analysis of the TOLEDO Study

P. Lewitt, R. Hauser, D. Kremens, A. Formella, M. Grall, M. Joshi, P. Qin (Detroit, USA)

Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease

M. Georgiades, D. Tsui, X. Chen, S. Bray, J. Qiu, S. Waller, L. Williams, S. Dal, T. Ong, A. Martin, H. Morales-Briceno, V. Fung (Sydney, Australia)

Continuous, Subcutaneous Apomorphine Infusion (CSAI) for PD: Development of a Phase IV routine practice study to capture the patient, care partner, and healthcare professional experience in the United States

M. Grall, A. Christiansen, N. Maskeri, S. Reyes, P. Qin, S. Isaacson (Rockville, USA)

Development and Validation of Personal Technology to Treat Hypophonia in Patients with Parkinson’s Disease

A. Klein, A. Gillespie, D. Anderson, M. Caveney, N. Sundholm (Atlanta, USA)

Dose Optimization of Foslevodopa/Foscarbidopa: Post Hoc Analysis of Study Completers

J. Aldred, M. Bouchard, D. Kern, P. Mir, L. Bergmann, R. Gupta, M. O'Meara, J. Samuelsson, B. Bergmans (Spokane, USA)

Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease

C. Onuigbo, J. Martinez-Lemus, T. Thomas, E. Tharp, J. Suescun, C. Green, T. Ellmore, E. Rodarte Rascon, R. Ritter, M. Schiess (Houston, USA)

Effect of CUE1+ Device on Motor and Non-Motor Symptoms in Parkinson’s: A Pilot Randomised Controlled Trial.

V. Azoidou, K. Rowsell, E. Camboe, K. Dey, A. Zirra, C. Quah, T. Boyle, C. Budu, D. Gallagher, A. Noyce, C. Simonet (London, United Kingdom)

Effect of Exenatide on disease progression in early Parkinson’s disease–a randomized, placebo controlled, single-center trial in Sweden

I. Markaki, CC. Tang, PE. Papathoma, L. Hainke, W. Paslawski, J. Paslawska, I. Savitcheva, U. Estenberg, D. Eidelberg, P. Svenningsson (Solna, Sweden)

Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial

J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Martins, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

Effect of Reaction Oriented Training on Postural Stability and Reaction Time in Parkinsons’s Disease

M. Salamci, A. Guclu-Gunduz, C. Ozkul, R. Yılmaz, M. Akbostancı (Ankara, Turkey)

Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease

E. Tharp, J. Martinez-Lemus, C. Onuigbo, T. Thomas, C. Green, J. Suescun, T. Le, E. Rodarte, R. Ritter Iii, T. Ellmore, M. Schiess (New York, USA)

Effects of Dynamic Neuro-Cognitive Imagery on FOG in People with Parkinson’s Disease: a Randomized Clinical Trial

P. Silva, K. Honda, L. Santos, J. Garcia, B. Silva, M. Piemonte (Sao Paulo, Brazil)

Efficacy and Safety of Different Apomorphine Formulations for OFF Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis

A. Abunamoos, M. Alghaniem, Y. Aljazi, F. Alnajjar, A. Al-Qudah, Q. Abulawi, M. Mustafa (Amman, Jordan)

Efficacy and Safety of IPX203 and Levodopa-Carbidopa Intestinal Gel (LCIG) Compared to Immediate-Release Carbidopa-Levodopa in Parkinson’s Disease: A Systematic Review and Meta-Analysis

M. Mustafa, A. Abunamoos, Y. Aljazi, F. Alnajjar, A. Sa’D, M. Alghaniem, K. Abuhananeh (Amman, Jordan)

Efficacy and safety of Rotigotine Extended-Release Microspheres in Early Parkinson’s Disease

H. Sun, X. Dan, H. Chen, J. Feng, W. Wang, Q. Ye, Y. Liu, C. Liu, S. Chen, P. Chan (Beijing, China)

Efficacy and Safety of Transcutaneous Auricular Vagal Stimulation on Gait in Patients with Parkinson’s Disease: a Systematic Review

K. Silva, L. Cabral, M. Kozlowski, W. Damasio (São José dos Campos, Brazil)

Efficacy of Combined Transcranial Direct Current Stimulation (tDCS) and Gait Training on Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

A. Hegazi, H. Hussein, R. Mohamed (Mansoura, Egypt)

Efficacy of ND0612 in Patients at Different Stages of Disease Severity: Subgroup-Analyses From a Randomized, Active-Controlled Study in People With Parkinson’s Disease Experiencing Motor Fluctuations

H. Sarva, R. Dhall, L. Lopez-Manzanares, J. Kulisevsky, N. Lopes, J. Pereira, S. Isaacson (New York, USA)

EJS ACT-PD: An Ongoing Initiative to Support Innovation and Sustainability of a Multi-Arm, Multi-Stage Platform Trial for Parkinson’s Disease

G. Mills, C. Gonzalez-Robles, M-L. Zeissler, O. Bandmann, R. Barker, J. Carpenter, S. Collins, J. Duffen, S. Gandhi, K. Mcfarthing, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

Enrollment Challenges and Strategies in Early-Stage Parkinson’s Disease Clinical Trials: Comparing Treatment-Naïve and Previously Treated Patient Populations

J. Roberts, A. Lysandropoulos (Durham, USA)

Establishing and Leveraging a Community Advisory Board to Guide Study Design, Speed Recruitment and Encourage Retention

C. Destro, M. Kuhl, C. Kelliher, R. Dobkin, S. Mantri, T. Tropea, A. Matthews, J. Carley, E. Flagg, W. Kutler (New York, USA)

Evaluation of Impact of Helicobacter Pylori Eradication on Symptomatology and Quality of Life in Parkinson’s Disease

A. Kakkar, G. Vishwas, S. Mehta, S. Pattanaik, S. Bhattacharyya, V. Sharma, M. Modi (Chandigarh, India)

Evaluation of Local Field Potential-guided DBS-programming in a Parkinson’s disease outpatient clinic

V. Zentsch, N. Warneke, I. Aymanns, D. Putzer, T. Huchtemann, T. Warnecke, I. Claus (Muenster, Germany)

Exploring Clinical and Neurophysiologic Predictors of Adaptive Deep Brain Stimulation Response in Parkinson’s disease

T. Herrington, M. Beudel, J. Ostrem, S. Little, A. Ramirez-Zamora, L. Almeida, A. Fasano, T. Hassell, K. Mitchell, E. Moro, M. Gostkowski, N. Sarangmat, L. Tonder, Y. Tan, R. Summers, S. Stanslaski, H. Bronte-Stewart (San Francisco, USA)

Exploring minzasolmin effect on digital measures captured by the Verily Study Watch in a subset of the ORCHESTRA trial participants

B. Bloem, V. Hinson, E. Goikoetxea, L. Gaetano, K. Ray, F. Ambrosetti, KC. Ho, M. Key Prato, A. Pethe, V. Ticcinelli, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants

L. Smits, Y. Zhang, C. Woodward, S. Aksenov, A. Costa Zaninotto, C. Donnelly, T. Storz, Y. Folami, P. Patel, C. Lubeski, M. Macdougall, K. Kelly, A. Hendricson, S. Korsten, P. Kremer, A. Cacace, I. Conti (Leiden, Netherlands)

Foscarbidopa/Foslevodopa Therapy Improves Continuous Duration of Good ON Time and Correlated With Quality of Life in People With Parkinson’s Disease

M. Bouchard, R. Hauser, P. Odin, D. Kern, S. Isaacson, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, C. Carroll (North Chicago, USA)

Functional and Neuroplastic Changes Following a 4-Week Non-Motorized Treadmill Training Program: A Pilot Study

A. Boddy, C. Smith, O. Salmon, M. Mastrodicasa, A. Silva, T. Barrett (Waco, USA)

G-Can, the GBA1 Canada Initiative

L. Chebon, P. Halder, E. Fon, T. Durcan, M. Parent, N. Dupre, M. Sharp, R. Postuma, G. Armstrong, A. Milnerwood, A. Dagher, J. Raamsdonk, J. Trempe, T. Goldsmith, X. Chen, N. Aprahamian, Z. You, M. Nicoleau, E. Deneault, A. Bayne, C. Laflamme, P. Mcpherson, M. Pandolfo, G. Rouleau, Z. Gan-Or (Québec, Canada)

GT-02287 in Parkinson’s Disease: Interim Data from a Phase 1b Study

R. Pozzi, T. Ignoni, M. Bosetti, M. Desciscio, A. Evans, V. Fung, A. Lehn, V. Miller, M. Rentería, R. Schwartz, D. Thyagarajan, S. Tisch, J. Taylor, J. Hannestad (Lugano, Switzerland)

Harnessing Digital Biomarkers to Monitor Early Parkinson’s Disease Progression

V. Shah, C. Silva-Batista, D. Engel, A. Ragothaman, P. Burgos, P. Carlson-Kuhta, F. Horak, M. Mancini (Philadelphia, USA)

Heat Map Visualization of Improved Best ON Time in People With Parkinson’s Disease Treated With Foscarbidopa/Foslevodopa

T. Henriksen, R. Hauser, I. Malaty, T. Kimber, M. Soileau, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, B. Bergmans (North Chicago, USA)

Honey products in Parkinson’s disease – randomized placebo-controlled double-blind pilot study

T. Endo, K. Toyooka, T. Matsumura, C. Mori, T. Saito, T. Saito, S. Sakoda (Toyonaka, Japan)

Identifying subjects at high risk for prodromal Parkinson’s Disease using dopamine transporter imaging deficit in a step-wise recruitment strategy: Data of Healthy Brain Ageing (HeBA)

S. Schade, C. Corinne, S. Ghosh, A. Garrido, E. Lang, P. Mahlknecht, C. Pauly, D. Pilco, R. Rautenkranz, K. Rege, S. Scaglione, S. Schnell, T. Wicke, V. Satagopam, M. Marti, E. Tolosa, W. Poewe, R. Krüger, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)

Immediate Impact of Whole-Body Vibration on Backward Walking in Individuals with Parkinson disease

A. Boddy, K. Barta, M. Flores, K. Sawyer, L. Perry, A. Campbell (Waco, USA)

Impact of Allogeneic Mesenchymal Stem Cells in Motor and Non-Motor Symptoms of Parkinson’s Disease: A Phase 2 Randomized Trial

M. Schiess, J. Martinez-Lemus, T. Thomas, E. Tharp, C. Onuigbo, J. Suescun, T. Ellmore, T. Le, E. Rodarte-Rascon, R. Ritter Iii, C. Green (Houston, USA)

Impact of Gastrointestinal Dysfunction Symptoms on Psychomotor Recovery Following 8-Week Aerobic Interval Training in Parkinson’s Disease – Preliminary Results

K. Lorek, K. Markowska, A. Bereza, E. Koziorowska, S. Budrewicz, P. Nowakowski, S. Chomiak (Wroclaw, Poland)

Impact of ND0612 on Levodopa-Induced Dyskinesia in Parkinson’s Disease: Post hoc Analyses From a Randomized, Active-Controlled Study

A. Ellenbogen, R. Pahwa, J. Hernández-Vara, N. Lopes, J. Pereira, A. Espay (Farmington Hills, USA)

Improvement of Freezing of Gait with Personalized Rhythmic Auditory Stimulation in Parkinson’s Disease

CH. Tsai, MC. Tsai, BL. Liu, KY. Hung, YK. Sek, HK. Chen, HC. Huang, MK. Lu, JR. Duann (Taichung, Taiwan)

Improvements in Motor and Non-Motor Symptoms of Parkinson’s Disease in Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study

A. Saltmarche, O. Hares, A. Liebert, B. Bicknell, M. Naeser, G. Heller, J. Sykes, K. Togeretz, A. Namini, G. Herkes (Toronto, Canada)

IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 6-year Interim Results

B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

Increased “Off” Time Is Associated With Poorer Clinical and Humanistic Outcomes in Patients With Advancing Parkinson’s Disease: Results From the PROSPECT Observational Study

P. Sanchez Alonso, D. Houghton, F. Ory-Magne, T. Oeda, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, S. Wang, C. Yan, D. Standaert (Majadahonda, Spain)

Increasing Physical Activity in Parkinson’s Disease Via a Remotely Deployed Gamification Intervention

J. Morley, K. Waddell, M. Smith, S. Wood, R. Greysen (Philadelphia, USA)

Independent and Synergistic Effects of Subthalamic Temporal Interference Stimulation on Motor Symptoms in Parkinson’s Disease

A. Li, J. Li, C. Zhang (Shanghai, China)

Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials

T. Mestre, J. Ding, N. Lapelle, G. Stebbins (Chicago, USA)

Long term real-world monitoring supports the superiority of adaptive deep brain stimulation: preliminary data on three patients with Parkinson’s disease

L. Caffi, R. Habib, L. Borellini, E. Mailland, F. Cogiamanian, M. Arlotti, L. Rossi, S. Bonvegna, C. Palmisano, S. Marceglia, A. Priori, G. Pezzoli, M. Locatelli, IU. Isaias (Würzburg, Germany)

Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings

J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, J. Holenz, W. Poewe (Lisbon, Portugal)

Long-term effects of a periodic intensive rehabilitation program in People with Parkinson’s Disease

Y. Yamaguchi, J. Ogawa, K. Kakegawa, M. Matsuda (Ginza, Chuo-ku, Japan)

Longitudinal Remote Monitoring with Wearable Technology in Parkinson Disease: Initiation of A Dyskinesia Insight Network Observational Study

R. Gilron, A. Hare, M. Grall, P. Qin, S. Isaacson (San Francsico, USA)

LRRK2 antisense oligonucleotide (BIIB094/ION859) impact on cerebrospinal fluid biomarkers in Parkinson’s disease patients

O. Mabrouk (cambridge, USA)

LRRK2 Pathway Inhibition By NEU-411, a Potent, Selective, CNS-Penetrant LRRK2 Inhibitor In Healthy Participants

C. Wong, S. Dheerendra, T. Dang, F. Nahab, J. Zheng, S. Savage, Z. Pei, C. Wynne, S. Jackson, L. Desnoyers (South San Francisco, USA)

Methodological considerations supporting a time-to-event primary endpoint in the PADOVA study in early-stage Parkinson’s disease participants on stable symptomatic treatment

N. Pross, G. Pagano, D. Trundell, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, A. Monnet, L. Rutten-Jacobs, G. Respondek, L. Boak, G. Kerchner, P. Brundin, H. Svoboda, T. Nikolcheva, A. Bonni (Basel, Switzerland)

Multipronged, Community-Engaged Approach to Recruiting Lewy Body Dementia Family Caregivers for a National Trial

J. Hemm, W. Ayele, S. Mitchell Chen, E. Stevens, A. Taylor, K. Fargo, D. Mariani, S. Seshadri, C. Bentley, T. Manak, A. Miller, C. Pensyl, C. Pierce, M. Voss, B. Ouyang, J. Chodosh, J. Fleisher (Chicago, USA)

Neural Mechanisms of Intermittent Theta Burst Stimulation for Depressive Symptoms in Parkinson’s Disease: Insights from fNIRS-Based Cortical Activation and Connectivity Dynamics

Y. Zhang, M. Hou, Z. Liu (Shanghai, China)

Opicapone in Parkinson’s Patients with Probable REM Sleep Behavior Disorder: Insights from the OASIS Trial

J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Magalhães, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

P2P Therapeutics Platform Trial in Stage 2B Neuronal Alpha-Synuclein Disease: Study Design and Statistical Considerations

T. Simuni, C. Coffey, A. Siderowf, C. Tanner, M. Brumm, S. Chowdhury, T. Sherer, C. Kopil, K. Kieburtz, C. Allen-Savietta, B. Wendelberger, A. Crawford, T. Tropea, K. Fabrizio, H. Whalen, K. Marek (Chicago, USA)

PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson’s disease participants on stable symptomatic treatment

T. Nikolcheva, G. Pagano, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, N. Pross, A. Monnet, G. Respondek, L. Rutten-Jacobs, V. Schlegel, L. Boak, G. Kerchner, P. Brundin, H. Svoboda, A. Bonni (Basel, Switzerland)

Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease

N. Vijiaratnam, C. Girges, J. Dickson, C. Caroll, M. Silverdale, M. Hu, G. Duncan, K. Chaudhuri, S. Gandhi, D. Athauda, Y. Li, N. Greig, K. Chowdhury, T. Foltynie (London, United Kingdom)

Pharmacokinetic Analysis of Subcutaneous Levodopa/Carbidopa Delivery With ND0612

L. Adar, N. Vostokova, I. Hadari Naor, G. Smania, M. Ibrahim, J. Pereira, I. Perlstein, M. Karlsson (Rehovot, Israel)

Phase I randomized, double-blind study to evaluate feasibility, safety, and clinical responses of implanting autologous peripheral nerve tissue into the nucleus basalis of Meynert or substantia nigra for non-motor or motor symptoms in patients with Parkinson’s disease undergoing DBS surgery (STAR) Trial

J. Quintero, J. Slevin, J. Hixson, G. Gerhardt, C. van Horne (Lexington, USA)

Physiological assessment of swallowing related muscles in patients with Parkinson’s disease: characteristics and utility of high-density surface electromyography

M. Nakamori, K. Yoshikawa, Y. Nishikawa, M. Toko, H. Yamada, H. Maruyama (Hiroshima, Japan)

Proof-of-Concept Study Design Leveraging Digital Biomarkers to Enhance Statistical Power and Reduce Sample Size in PD Trials

S. Hendrix, J. Christensen, S. Jackson, P. O'Keefe, K. Hendrix, S. Dheerendra, F. Nahab, S. Dickson (Millcreek, USA)

Quality of Life Improvements in Parkinson’s Disease for Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study

A. Saltmarche, O. Hares, A. Liebert, B. Bicknell, M. Naeser, G. Heller, J. Sykes, K. Togeretz, A. Namini, G. Herkes (Toronto, Canada)

Random-Order Crossover Trial Assessing the Safety, Feasibility and Exploratory Efficacy of Two Mediterranean-Ketogenic Nutritional Interventions in Parkinson’s Disease

K. Tosefsky, J. Lam, Y. Wang, A. Kuan, S. Appel-Cresswell (Vancouver, Canada)

Randomized Trial comparing Directional DBS with Ring-mode DBS in PD

V. Sisodia, TR. Ten Brinke, H. Jergas, VJJ. Odekerken, D. Verbaan, JM. Dijk, M. Bot, M. Beudel, P. Munckhof, MT. Barbe, PR. Schuurman, RMA. de Bie (Amsterdam, Netherlands)

Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study

S. Isaacson, F. Stocchi, A. Ellenbogen, N. Lopes, N. Sasson, J. Pereira, O. Rascol (Boca Raton, USA)

Remote Deep Brain Stimulation Programming for Parkinson’s Disease: A Multicenter Randomized Non-Inferiority Trial

J. Shaik, V. Zentsch, C. Buhmann, T. Kinfe, M. Regensburger, J. Rumpf, A. Schnitzler, G. Höglinger, J. Mehrkens, T. Koeglsperger (Muenster, Germany)

Results From a Dose-Blinded, Phase II Extension Study Evaluating Long-Term Efficacy, Safety and Tolerability of Minzasolmin in Participants With Parkinson’s Disease

C. Beuter, S. Carson, M. Key Prato, N. Massat, R. Maguire, A. Dhar Koul, E. Lucassen, J-M. Riethusien, I. Giunzioni, A. Pethe, G. Goethals, A. Khanna, Z. Ali (Monheim am Rhein, Germany)

Results from the PRIME-UK Randomised Controlled Trial

K. Lloyd, E. Tenison, C. Mcdonald, S. Haworth, C. Glover, R. Harrison, D. Pendry-Brazier, M. Smith, F. Lithander, A. Cullen, K. Naylor, N. Giles, T. Gabriel, P. Kamnerdsupaphon, A. Nodehi, Y. Ben-Shlomo, EJ. Henderson (Bristol, United Kingdom)

Retention & Safety in a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo (TOPAZ) in Persons with Neurodegenerative Parkinsonism (NDP)

C. Tanner, N. Luthra, S. Goldman, R. Zuzuarregui, E. Brown, C. Meng, J. Perkins, L. Racelo, T. Hue, C. Schambach, D. Kriesel, H. Barnes, T. Stiep, I. Bledsoe, P. Ranola, M. Schwarzschild, R. Dorsey, A. Espay, S. Krischer, C. Comella, M. Siddiqui, F. Gao, M. Ledoux, E. Byrd, I. Litvan, N. Mcfarland, K. Mitchell, D. Standaert, J. Beck, K. Williams, M. Drake, D. Bauer, K. Lyles, S. Cummings, THE. Topaz Study-Team (San Francisco, USA)

Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose

J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, D. Ramos, J. Holenz, W. Poewe (Lisbon, Portugal)

Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study

M. Cai, J. Wei, X. Ren, R. Yan, H. Chen, N. Xiong (Chengdu, China)

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Vent-02, a Novel CNS-Penetrant NLRP3 Inhibitor for the Treatment of Parkinson’s Disease

A. Matta, X. Valencia, L. Warner, K. Pike, C. Winters, L. Smidt, M. Moerland, O. Spiegelstein (Waltham, USA)

Screening for Neuronal Synuclein Disease (NSD) using cerebrospinal fluid (CSF) in the Parkinson Progression Marker Initiative (PPMI)

J. Dimos, B. Mcmahon, L. Lemon, A. Siderowf, T. Simuni, C. Tanner, K. Marek, C. Coffey, T. Foroud, L. Chahine, E. Brown, T. Tropea, M. Kuhl, A. Bright, M. Totten, G. Antonopoulos, L. Heathers (New Haven, USA)

SL-START: A Multicentre Observational Study of Sublingual Apomorphine Titration and Usage Schemes in Routine Practice

J. Kassubek, P. Themann, H. Brigas, C. Maganete, G. Harrison-Jones, I. Pijuan Jiménez (Ulm, Germany)

Smartphone-based digital assessments in the LUMA trial of BIIB122 for early-stage Parkinson’s disease

R. Llorens Arenas, J. Edgerton, E. Bartholomé, S. Belachew, M. Gifford, J. Guo, B. Hersh, D. Jennings, C. Kanzler, E. Koca, M. Pang, O. Reyes, C. Shen, M. Wald, N. Woody, C. Mazzá (Cambridge, USA)

Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Parkinson’s Disease (PD)

S. Isaacson, K. Chou, H. Sarva, S. Merchant, C. Scholl, M. Charles, N. Brice, L. Dawson, M. Carlton, S. Vaidya, K. Kieburtz, R. Hauser, A. Ellenbogen (Ann Arbor, USA)

Targeting inflammation and autophagy: a dual-inhibition strategy to reduce α-synuclein pathology in GBA1-associated Parkinson’s disease

T. Usenko, A. Bezrukova, K. Basharova, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

Tavapadon Is Not Associated With Increased Daytime Sleepiness in People With Parkinson’s Disease

R. Pahwa, Z. Mari, W. Ondo, L. Harmer, A. Lind, R. Hauser (Kansas City, USA)

The Benefits of Whole-Body Electro Muscle Stimulation (WB-EMS) in a patient with Parkinson’s Disease

N. Duff, C. Cawood, M. Noble (Parktown, South Africa)

The NICE-PD Trial: Cost-Effectiveness of Specialized Nursing Interventions for People with Parkinson’s Disease

D. Radder, B. Maas, E. Zeeboer, H. Lennaerts, L. Ter Brake, E. Adang, J. Int Hout, H. Vermeulen, T. van Asseldonk, C. Delnooz, R. Hagen, M. Munneke, B. Bloem, N. de Vries (Nijmegen, Netherlands)

Trans-Spinal Theta Burst Magnetic Stimulation Enhances Treadmill Training Effects on Gait in Parkinson’s Disease

L. Lopes, J. Oliveira, A. Costa-Ribeiro, K. Monte-Silva, C. Souza, M. de Melo, M. Gomes, L. Shirahige, R. Albuquerque, R. Carra, C. Tanaka, E. Barbosa, D. de Andrade, R. Cury (Sao Paulo, Brazil)

Trends on recruitment and retention in Parkinson’s Disease modification trials

D. Hengartner, R. Palacio, J. Garinger, A. Lysandropoulos (Durham, USA)

Unilateral focused ultrasound subthalamotomy in early Parkinson’s disease: randomized-controlled trial protocol

R. Martinez-Fernandez, MC. Rodriguez Oroz, S. Paschen, C. Juri, M. Del Alamo, E. Natera-Villalba, R. Rodriguez-Rojas, LH. Gonzalez-Quarante, M. Synowitz, J. Lorenzoni, CA. Sánchez-Catasús, S. Obika, T. Jimenez-Castellanos, P. Reiters, E. Cerutti, RA. Villino-Boquete, C. Ferrer, O. Rascol, G. Deuschl, JA. Obeso (Madrid, Spain)

VGN-R09b, an Adeno-associated virus-based Combination Gene Replacement Therapy for Parkinson’s Disease

YZ. Tao, SS. Tian, L. Lu, X. Zhu, H. Lv, XP. Zhao (Shanghai, China)

Wearable-based digital measures from the Verily Study Watch can detect concurrent symptomatic treatment effects in a subset of early-stage Parkinson’s disease ORCHESTRA trial participants

B. Bloem, V. Hinson, L. Gaetano, E. Goikoetxea, K. Ray, F. Ambrosetti, V. Ticcinelli, M. Key Prato, A. Pethe, C. Serrano Amenos, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

Who is lost? Monitoring recruitment in the EJS ACT-PD trial to improve understanding of inclusive recruitment

M-L. Zeissler, R. Davidson, K. Hockey, G. Mills, R. Petty, C. Pugh, T. Liddle, Y. Yiannakou, T. Foltynie, C. Carroll (Newcastle upon Tyne, United Kingdom)